Navigation Links
UCSF researchers identify new drug target for Kaposi's sarcoma
Date:7/30/2009

UCSF researchers have identified a new potential drug target for the herpes virus that causes Kaposi's sarcoma, re-opening the possibility of using the class of drugs called protease inhibitors against the full herpes family of viruses, which for 20 years has been deemed too difficult to attain.

The new drug target, which is known as a protease dimer, could serve as a model for developing new therapeutics for diseases ranging from cancer to Alzheimer's, the researchers say. Findings are reported in the Advance Online Publication section of the "Nature Chemical Biology" web site and can be found at www.nature.com/nchembio/index.html.

Most current antiviral drugs target the active sites of viral proteins, where enzymes and receptors work in a lock-and-key approach to either activate or deactivate that particular protein, the researchers explained. Traditionally, drug development has focused on inhibiting that lock-and-key action to prevent the enzyme, or receptor from being effective.

Some viral enzymes known as proteases, however, including those for HIV and the herpes virus family, take the form of a dimer, or two identical halves much like a fully opened clamshell in their most stable state. Those proteases play an essential role in making the virus infectious, but require the two clamshell halves to bind together to be activated, according to the paper.

The HIV protease was successfully targeted for drug development in the 1980s, by blocking the active site on the surface of the dimer, but the herpes virus protease dimer has consistently eluded efforts to disrupt it at its active site, the researchers said.

The UCSF team set out to find ways to instead prevent the two halves of the dimer from connecting at that clamshell joint, to prevent it from activating. What they found was a new target on the unstable, monomer form of the protease, which respond
'/>"/>

Contact: Kristen Bole
kbole@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Fox Chase researchers uncover one force behind the MYC oncogene in many cancers
2. 1 in 6 health workers wont report in flu pandemic -- study by Ben-Gurion U. researchers
3. Researchers team up to provide new hope for childhood hunger
4. UBC researchers help push for standard DNA barcodes for plants
5. Researchers develop brain-reading methods
6. ISU researchers find possible treatment for spinal muscular atrophy
7. Researchers capture bacterial infection on film
8. Researchers design first model motor nerve system thats insulated and organized like the human body
9. Iowa State University researchers develop process for surgical genetic changes
10. UCLA researchers discover new molecular pathway for targeting cancer, disease
11. Munich researchers discover new target for tailored antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... in New Mexico, nearly every public golf course is ... potable water supplies. Across the U.S. Southwest as a ... treated effluent. Reusing the effluent increases the sustainability of ... alike fertilize their lawns during the growing season. The ... State University turfgrass expert has a new vision for ...
(Date:7/10/2014)... YORK , June 27, 2014  Pomerantz ... Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) ... filed in United States District Court, Middle District ... is on behalf of a class consisting of ... acquired Provectus securities between December 17, 2013 and ...
(Date:7/10/2014)... SPRINGS, Florida , July 1, 2014 ... wallets pave way for convenience and improved security: NXT-ID, Inc. ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... and MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) ... is pleased to announce that the second series of 30 ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5
... 22, 2011 - The Vilcek Foundation is pleased to announce ... of foreign-born scientists and artists. The sixth annual ... sustained record of innovation and achievement, is awarded to Dutch-born ... of the laboratory of Cell Biology and Genetics at Rockefeller ...
... (BRONX, NY) Ertuğrul zbudak, Ph.D. , assistant ... of Medicine of Yeshiva University, has won a ... his research into the genetic causes of vertebral malformations that ... adult diseases, including scoliosis, disfigurement, and back and neck pain. ...
... 2011) -- A lab at Rice University has stepped forward ... that preserves their unique properties -- and adds more. ... functionalities to remain in close contact with single-walled carbon nanotubes ... separation is critical to manufacturers who want to spin fiber ...
Cached Biology News:Vilcek Foundation names recipients of 2011 Vilcek Prizes in Biomedical Science 2Vilcek Foundation names recipients of 2011 Vilcek Prizes in Biomedical Science 3Albert Einstein College of Medicine geneticist wins Sloan Research Fellowship 2Metallic molecules to nanotubes: Spread out! 2Metallic molecules to nanotubes: Spread out! 3
(Date:7/10/2014)... July 10, 2014  Franciscan St. Anthony ... capnography for respiratory monitoring outside the operating ... leaders in embracing state-of-the-art patient safety technology. ... are breathing and can alert medical caregivers ... the amount of carbon dioxide the patient ...
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
(Date:7/10/2014)... July 10, 2014 Research and Markets ... the "International Photonic Integrated Circuit (Monolithic Integration, ... 2019" report to their offering. ... concept of photonic integration traces its roots in ... promise of photonic integration went unexplored and unfulfilled ...
(Date:7/10/2014)... -- According to the International Atomic Energy Agency ... from terrorists acquiring sufficient quantities of plutonium or ... nuclear explosive device. The IAEA also notes that ... gram-level quantities, which can be challenging to detect ... new study appearing this week in the ...
Breaking Biology Technology:Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Sensitive detection method may help impede illicit nuclear trafficking 2
... , FLORHAM PARK, N.J., June 1 Today, BASF filed ... District of Delaware against DuPont (E. l. du Pont de ... confers tolerance to a key class of herbicides. Specifically, DuPont,s ... an important genetic component that enables successful tolerance toward an ...
... NOVATO, Calif., June 1 Raptor Pharmaceuticals Corp. ... today announced that it has dosed the first ... in collaboration with the University of California, ... delayed-release cysteamine bitartrate ("DR Cysteamine") capsules in nephropathic ...
... - Results Presented at American Society of Clinical Oncology ... with Favorable Pharmacokinetics and Prolonged Stable Disease in Refractory ... Mersana Therapeutics presented preliminary results of a Phase ... in a poster session at the 2009 Annual Meeting ...
Cached Biology Technology:BASF Sues DuPont for Patent Infringement 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 3Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 4Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 5Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors 2Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors 3
... to Ki67 - Proliferation Marker, prediluted ... related nuclear protein, expressed by proliferating cells ... cycle (G1, S, G2 and M phase). ... Ki67 antibodies are useful in establishing the ...
Request Info...
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
Biology Products: